<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Dawber RS</submitter><funding>MRC Discovery Medicine</funding><funding>Biotechnology and Biological Sciences Research Council</funding><funding>Engineering and Physical Sciences Research Council</funding><pagination>e70086</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12867955</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>32(3)</volume><pubmed_abstract>Orthosteric inhibition of the N-Myc/Aurora-A protein-protein interaction (PPI) represents a potential mechanism by which degradation of N-Myc can be induced, given its interaction with Aurora-A competes with the factors that tag it for proteasomal degradation. As such, this would constitute an approach for the development of drugs to treat neuroblastoma, a childhood cancer that depends upon N-Myc. Reactive electrophiles have proven useful in the context of targeted covalent inhibitors, and in this work, we sought to improve the potency of a previously identified N-Myc-derived peptide by introducing a sulfonyl fluoride warhead. We successfully demonstrated selective labelling of Aurora-A using the resultant peptidomimetics and established this labelling as recognition-directed, providing va</pubmed_abstract><journal>Journal of peptide science : an official publication of the European Peptide Society</journal><pubmed_title>Covalent Peptide-Based N-Myc/Aurora-A Inhibitors Bearing Sulfonyl Fluoride Warheads.</pubmed_title><pmcid>PMC12867955</pmcid><funding_grant_id>BB/V003577/1</funding_grant_id><funding_grant_id>EP/V029169/1</funding_grant_id><funding_grant_id>BB/V003577/2</funding_grant_id><funding_grant_id>MR/N013840/1</funding_grant_id><pubmed_authors>Wright MH</pubmed_authors><pubmed_authors>Bayliss R</pubmed_authors><pubmed_authors>Gimenez D</pubmed_authors><pubmed_authors>Wilson AJ</pubmed_authors><pubmed_authors>Preston GW</pubmed_authors><pubmed_authors>Warriner SL</pubmed_authors><pubmed_authors>Dawber RS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Covalent Peptide-Based N-Myc/Aurora-A Inhibitors Bearing Sulfonyl Fluoride Warheads.</name><description>Orthosteric inhibition of the N-Myc/Aurora-A protein-protein interaction (PPI) represents a potential mechanism by which degradation of N-Myc can be induced, given its interaction with Aurora-A competes with the factors that tag it for proteasomal degradation. As such, this would constitute an approach for the development of drugs to treat neuroblastoma, a childhood cancer that depends upon N-Myc. Reactive electrophiles have proven useful in the context of targeted covalent inhibitors, and in this work, we sought to improve the potency of a previously identified N-Myc-derived peptide by introducing a sulfonyl fluoride warhead. We successfully demonstrated selective labelling of Aurora-A using the resultant peptidomimetics and established this labelling as recognition-directed, providing va</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Mar</publication><modification>2026-07-15T06:37:34.935Z</modification><creation>2026-07-02T03:08:38.759Z</creation></dates><accession>S-EPMC12867955</accession><cross_references><pubmed>41634954</pubmed><doi>10.1002/psc.70086</doi></cross_references></HashMap>